Enphase Energy Inc vs Zimmer Biomet Holdings Inc — how do they compare? Enphase Energy Inc trades at $40.89 (market cap $5.59B), while Zimmer Biomet Holdings Inc trades at $96.1 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 3.3× Enphase Energy Inc's market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals.
| ENPH | ZBH | |
|---|---|---|
Market Cap | $5.59B | $18.55B |
Sector | Technology | Health |
52-Week High | $72.33 | $107.71 |
52-Week Low | $26.12 | $79.58 |
Enterprise Value | $5.23B | $25.61B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $41.06, up 0.34% with a bullish technical outlook supported by moving averages. The company reported mixed Q2 2026 earnings matching estimates but missing revenue expectations, with revenue declining 19.6% year-over-year. Recent developments include expanded battery system support and US manufacturing commitments. Valuation metrics show a P/E of 41.88 and P/S of 4.25, while profitability remains solid with 10.09% net income margin.
The stock presents recovery potential with analyst consensus target of $45.37 (10.5% upside), though faces headwinds from cyclical residential solar demand and competitive pressures. Key risks include execution challenges in European expansion and AI data center strategy, while institutional interest remains mixed with recent insider selling activity.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Trailing returns across standard periods
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →